Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial. Abstract: ...
酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)是驱动基因阳性晚期非小细胞肺癌(non⁃small cell lung cancer,NSCLC)的一线治疗选择,显著改善了该类患者的预后[1]。然而TKIs的血药浓度及疗效因受细胞色素P450(cytochrome P450,CYP)酶和转运体基因多态性、患者依从性、药物相互作用等因素的影响而出现个体差异较大...
CA Cancer J. Clin. 73, 17–48 (2023). Article PubMed Google Scholar Wang, Y. et al. Survival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: a Surveillance, Epidemiology, and End Results database-based...
Relative survival rates for non-small-cell lung cancer (NSCLC): Almost 90% of lung cancers are this type. The National Cancer Institute’s database breaks down the cancers by how far the tumors have spread. These relative survival rates are the average percentages of people who are alive 5...
The average five-year survival rate for all stages of renal cell carcinoma combined is more than 60 percent. The five-year survival rate is very low once the cancer has spread to distant organs. Survival is considerably higher when the cancer is detected early; many of these patients often ...
The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.
cancer growth and survival. Indeed, cancer can be managed by blocking the target genes related to tumor cell progression without causing noticeable damage to normal cells. Currently, efforts have been focused on improving the targeted therapy aspects regarding the encouraging outcomes in cancer ...
Non-Small Cell Lung CancerPrognosisSurvival RateTumor StagingIntroduction: Long-term survival (LTS) is an important goal of lung cancer treatment. Patients with metastatic disease at presentation have a median survival of 8 - 10 months. We sought to elucidate variables affecting 3-year survival of...
Lung cancer is the leading cause of cancer-associated mortality worldwide1. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx s
Small cell lung cancer (SCLC) is a type of lung cancer that develops quickly, is aggressive, and has a high fatality rate [1,2]. Although the incidence of SCLC is only 15% of all lung cancer, which is much lower than that of non-small cell lung cancer (NSCLC), SCLC has th...